OncoMatch/Clinical Trials/NCT07075185
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Is NCT07075185 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies KLN-1010 for multiple myeloma in relapse.
Treatment: KLN-1010 — The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: cd38-directed monoclonal antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07075185 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory drug.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages